Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Motor neuron disease in 2017

Progress towards therapy in motor neuron disease

Nature Reviews Neurology volume 14, pages 65–66 (2018)Cite this article

Subjects

In 2017, dramatic advances have been made in the treatment of motor neuron diseases. New therapies have been approved for spinal muscular atrophy and amyotrophic lateral sclerosis, and a host of other therapies that are currently under development are showing promising results.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Therapeutic advances across the motor neuron disease landscape.

References

  1. Eisen, A. et al. Cortical influences drive amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 88, 917–924 (2017).

    Article  Google Scholar 

  2. Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017).

    Article  CAS  Google Scholar 

  3. The Writing Group. Safety and efficacy of edaravone inwell defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505–512 (2017).

  4. Mora, J. S., Barbeito, L. & Hermine, O. Masitinib as an add-on therapy to riluzole is beneficial in the treatment of amyotrophic lateral sclerosis (ALS) with acceptable tolerability: results from a randomized controlled phase 3 trial. European Network to Cure ALS (ENCALS) http://videolectures.net/encals2017_barbeito_mora_hermine_therapy/ (2017).

  5. Meininger, V. et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 16, 208–216 (2017).

    Article  CAS  Google Scholar 

  6. van Eijk, R. P. A. et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2017-317077 (2017).

    Article  Google Scholar 

  7. McLaughlin, R. L. et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat. Commun. 8, 14774 (2017).

    Article  CAS  Google Scholar 

  8. Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942–955 (2011).

    Article  CAS  Google Scholar 

  9. Turner, M. R. & Kiernan, M. C. The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder. J. Neurol. Neurosurg. Psychiatry 86, 481–482 (2015).

    Article  Google Scholar 

  10. van Eijk, R. P. A., et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 89, 1915–1922 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

M.C.K. is supported by funding from the National Health and Medical Research Council of Australia (Program Grant #1037746).

Author information

Authors and Affiliations

  1. Matthew C. Kiernan is at the Brain and Mind Centre, University of Sydney, New South Wales 2040, Australia.,

    Matthew C. Kiernan

Authors
  1. Matthew C. Kiernan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew C. Kiernan.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kiernan, M. Progress towards therapy in motor neuron disease. Nat Rev Neurol 14, 65–66 (2018). https://doi.org/10.1038/nrneurol.2017.186

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.186

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing